A Phase I, Open-label Study to Evaluate the Pharmacokinetics of Single and Multiple Doses of Epanova® in Chinese Healthy Subjects Living in China
Latest Information Update: 04 Nov 2021
At a glance
- Drugs Omega-3 carboxylic acids (Primary)
- Indications Hypertriglyceridaemia; Non-alcoholic fatty liver disease
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 04 Jul 2018 New trial record
- 03 Jul 2018 Status changed from recruiting to completed.